Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit

J J X Lee; D W-M Tai; S P Choo

doi:10.1016/j.esmoop.2021.100129

Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit

ESMO Open. 2021 Jun;6(3):100129. doi: 10.1016/j.esmoop.2021.100129. Epub 2021 Apr 20.

Authors

J J X Lee¹, D W-M Tai¹, S P Choo²

Affiliations

¹ Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
² Division of Medical Oncology, National Cancer Centre Singapore, Singapore. Electronic address: choo.su.pin@singhealth.com.sg.

Abstract

With increasing therapeutic options available for advanced hepatocellular carcinoma (HCC), the timing and sequencing of locoregional and systemic therapy need to be re-examined. This is especially so for patients with intermediate HCC, so as to optimize responses while preserving liver reserves, and in so allowing our patients to achieve the best survival outcomes possible.

Keywords: hepatocellular carcinoma; locoregional therapy; sequencing of therapy; systemic therapy.

Publication types

Review

MeSH terms

Carcinoma, Hepatocellular* / therapy
Chemoembolization, Therapeutic*
Humans
Liver Neoplasms* / therapy